APA (7th ed.) Citation

LN, G., AG, B., F, M., N, K., B, W., D, L., . . . Jr, G. L. (2025). Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States. Journal of medical economics, 28(1), 910. https://doi.org/10.1080/13696998.2025.2514909

Chicago Style (17th ed.) Citation

LN, Gordan, et al. "Cost Per Responder for Teclistamab and Elranatamab in Relapsed or Refractory Multiple Myeloma in the United States." Journal of Medical Economics 28, no. 1 (2025): 910. https://doi.org/10.1080/13696998.2025.2514909.

MLA (9th ed.) Citation

LN, Gordan, et al. "Cost Per Responder for Teclistamab and Elranatamab in Relapsed or Refractory Multiple Myeloma in the United States." Journal of Medical Economics, vol. 28, no. 1, 2025, p. 910, https://doi.org/10.1080/13696998.2025.2514909.